# Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia

Study · id `cardio:ct-nct01564875` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01564875](<https://clinicaltrials.gov/study/NCT01564875>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01564875

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 122 participants.

## Technical summary

Registry record NCT01564875. Randomized; triple masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2012-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 122 participants (enrolled count; ClinicalTrials.gov record NCT01564875, source copy `cardio:ctgov-nct01564875-2012-03-28`, retrieved 2026-10-26)
- Start date: 2010-12 (registry gives no type) (ClinicalTrials.gov record NCT01564875, source copy `cardio:ctgov-nct01564875-2012-03-28`, retrieved 2026-10-26)
- Primary completion: 2012-05 (anticipated) (ClinicalTrials.gov record NCT01564875, source copy `cardio:ctgov-nct01564875-2012-03-28`, retrieved 2026-10-26)
- Completion: 2012-05 (anticipated) (ClinicalTrials.gov record NCT01564875, source copy `cardio:ctgov-nct01564875-2012-03-28`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01564875, source copy `cardio:ctgov-nct01564875-2012-03-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01564875-2012-03-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia
- Acronym: HM-SIM4
- Condition: Chronic Kidney Disease
- Condition: Hyperlipidemia
- Intervention (Drug): Simvast CR
- Intervention (Drug): Zocor
- Lead sponsor: Hanmi Pharmaceutical Company Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry intervention name matches this record: Simvastatin (`cardio:simvastatin`)
- Registry lists this organization as the lead sponsor: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)

## Provenance

Content hash: 4511912afc9fc220d2a647a6b9bdad6879026196c596db0a5ee3e2973a243de5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
